ES2190311A1 - Gene for fructose hereditary intolerance therapy consists of a promoter linked to fructoquinase cDNA - Google Patents

Gene for fructose hereditary intolerance therapy consists of a promoter linked to fructoquinase cDNA

Info

Publication number
ES2190311A1
ES2190311A1 ES200002221A ES200002221A ES2190311A1 ES 2190311 A1 ES2190311 A1 ES 2190311A1 ES 200002221 A ES200002221 A ES 200002221A ES 200002221 A ES200002221 A ES 200002221A ES 2190311 A1 ES2190311 A1 ES 2190311A1
Authority
ES
Spain
Prior art keywords
gene
fructose
hereditary
fructoquinase
intolerance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200002221A
Other languages
Spanish (es)
Other versions
ES2190311B1 (en
Inventor
Albinana Juan Emilio Feliu
Gutierrez Julio Cesar Sanchez
Tubert Fatima Bosch
Altarriba Anna Pujol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Autonoma de Madrid
Universitat Autonoma de Barcelona UAB
Original Assignee
Universidad Autonoma de Madrid
Universitat Autonoma de Barcelona UAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Autonoma de Madrid, Universitat Autonoma de Barcelona UAB filed Critical Universidad Autonoma de Madrid
Priority to ES200002221A priority Critical patent/ES2190311B1/en
Publication of ES2190311A1 publication Critical patent/ES2190311A1/en
Application granted granted Critical
Publication of ES2190311B1 publication Critical patent/ES2190311B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Chimaeric gene for the development of a therapeutic approach to hereditary fructose intolerance. It consists of a promoter tied to the gene or the DNAc of fructokinase. The chimaeric gene is inserted in a liver cell, allowing the fructokinase to act. It also refers to a transgenic animal whose genome includes this chimaeric gene, with the animal developing disorders associated with hereditary intolerance to fructose after fructose, sorbitol or saccharose has been administered.< IMAGE >The gene for fructose hereditary intolerance therapy comprises a promoter linked to the gene or the cDNA of fructoquinase. It is inserted in a hepatic cell to permit expression of fructoquinase.
ES200002221A 2000-08-31 2000-08-31 CHEMICAL GENE FOR THE DEVELOPMENT OF THERAPEUTIC APPROXIMATIONS TO HEREDITARY INTOLERANCE TO FRUCTOSE. Expired - Lifetime ES2190311B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200002221A ES2190311B1 (en) 2000-08-31 2000-08-31 CHEMICAL GENE FOR THE DEVELOPMENT OF THERAPEUTIC APPROXIMATIONS TO HEREDITARY INTOLERANCE TO FRUCTOSE.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200002221A ES2190311B1 (en) 2000-08-31 2000-08-31 CHEMICAL GENE FOR THE DEVELOPMENT OF THERAPEUTIC APPROXIMATIONS TO HEREDITARY INTOLERANCE TO FRUCTOSE.

Publications (2)

Publication Number Publication Date
ES2190311A1 true ES2190311A1 (en) 2003-07-16
ES2190311B1 ES2190311B1 (en) 2004-06-16

Family

ID=27589265

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200002221A Expired - Lifetime ES2190311B1 (en) 2000-08-31 2000-08-31 CHEMICAL GENE FOR THE DEVELOPMENT OF THERAPEUTIC APPROXIMATIONS TO HEREDITARY INTOLERANCE TO FRUCTOSE.

Country Status (1)

Country Link
ES (1) ES2190311B1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075229A (en) * 1987-06-16 1991-12-24 Ohio University Edison Animal Biotechnology Center Dietary and hormonal regulation of expression of exogenous genes in transgenic animals under control of the promoter of the gene for phosphoenolpyruvate carboxykinase
WO1995025169A1 (en) * 1994-03-14 1995-09-21 Universitat Autonoma De Barcelona CHIMERIC GENE USING THE GENE OR cDNA OF INSULINE, SPECIALLY FOR THE GENE THERAPY OF DIABETES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075229A (en) * 1987-06-16 1991-12-24 Ohio University Edison Animal Biotechnology Center Dietary and hormonal regulation of expression of exogenous genes in transgenic animals under control of the promoter of the gene for phosphoenolpyruvate carboxykinase
WO1995025169A1 (en) * 1994-03-14 1995-09-21 Universitat Autonoma De Barcelona CHIMERIC GENE USING THE GENE OR cDNA OF INSULINE, SPECIALLY FOR THE GENE THERAPY OF DIABETES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAYWARD B.E. et al: 'Structure and alternative splicing of the ketohexokinase gene', Eur. J. Biochem., Octubre 1998, Vol. 257, No. 1, paginas 85-91 *

Also Published As

Publication number Publication date
ES2190311B1 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
EP1245676A4 (en) Human monoclonal antibodies against tgf-beta ii receptor and medicinal use thereof
ES296615U (en) Transdermal therapeutic system having improved delivery characteristics
BR0015567A (en) Phenoxycarboxylic acid compounds and compositions for releasing active agents
FI971172A (en) Method for preparing dosage units by wet granulation
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
ES2173420T3 (en) TABLETS CONTAINING AN ANTIBIOTIC BETA-LACTAMIC AND PROCEDURE FOR PRODUCTION.
EA200201000A1 (en) HORMONE-DESTINY THERAPY
DK1206261T3 (en) Pharmaceutical preparations comprising clavanoic acid or derivatives thereof for the treatment of behavioral diseases
EP1023315A4 (en) Methods and compositions for destruction of selected proteins
MA23170A1 (en) PROCESS FOR THE PREPARATION OF A NEW COMPOUND.
AU2001269936A1 (en) Transgenic algae for delivering antigens to an animal
NO20022966L (en) Drospirenone for hormone replacement therapy
WO2000061069A3 (en) Methods and compositions for use in the treatment of hyperlipidemia
HK1100814A1 (en) Use of non-sedating barbiturate compounds in preparation of neuroprotective agents
DK0837935T3 (en) The 3 &#39;untranslated region of the human prohibitin gene
CR10289A (en) &#34;STRATRIENS 9-ALFA-SUBSTITUTED AS SELECTIVE EFFECTIVENESS STROGENS&#34; (DIVISIONAL)
PT1039900E (en) THERAPEUTIC AGENTS
ES2190311A1 (en) Gene for fructose hereditary intolerance therapy consists of a promoter linked to fructoquinase cDNA
EP1287019A4 (en) Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
MXPA01012936A (en) Pharmaceutical composition containing sibutramine and orlistat.
EP1303520A4 (en) Therapeutic compounds and methods
DK0711163T3 (en) Use of benzydamine in the treatment of pathological conditions caused by TNF
Hosseinzadeh Sahafi et al. Ornamental fish atlas of Kish Island
TR200102262T2 (en) Method for preventing or reducing cardiovascular events related to coronary intervention.
Tokar Transitioning to Ada 9X: Tartan's position

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030716

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2190311B1

Country of ref document: ES